| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| InflaRx N.V. | Vilobelimab (IFX-1) | Pyoderma Gangrenosum (PG) | Phase 3 | Trial Discontinued | Intravenous | Immunology |
| InflaRx N.V. | Vilobelimab (IFX-1) - (IXPLORE) | ANCA-associated vasculitis (AAV) | Phase 2 | Trial Discontinued | Intravenous | Immunology |
| InflaRx N.V. | Vilobelimab (IFX-1) | Hidradenitis Suppurativa | Phase 2 | Trial Completed | Intravenous | Immunology: Anti-TNF |
| InflaRx N.V. | Izicopan (INF904) | Chronic Autoimmune and Inflammatory Diseases | Phase 2a | Data Released | Oral | Immunology |
| Inhibikase Therapeutics Inc. | Risvodetinib - (IkT-148009) - (201 trial) | Parkinson’s disease | Phase 2 | Trial Discontinued | Oral | Neurology |
| Inhibikase Therapeutics Inc. | IkT-001Pro | Blood and Gastrointestinal Cancers | NDA Filing | Type Meeting | Oral | Oncology |
| Inhibikase Therapeutics Inc. | risvodetinib (IkT-148009) - (202 trial) | Multiple System Atrophy (MSA) | Phase 2a | Looking for Funding | oral | Neurology |
| Inhibikase Therapeutics Inc. | IKT-001 - (IMPROVE-PAH) | Pulmonary Arterial Hypertension | Phase 3 | Trial Planned | Oral | Cardiology |